[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635578":3},{"organization":4,"outcomesModule":7,"designInfo":27,"detailedDescription":30,"studyPopulation":31,"armGroups":32,"interventions":26,"overallOfficials":26,"centralContacts":36,"locations":42,"responsibleParty":54,"collaborators":26,"id":58,"slug":26,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":26,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":26,"enrollmentInfo":66,"targetDuration":26,"studyType":69,"phases":26,"briefSummary":70,"conditions":71,"keywords":26,"overallStatus":73,"whyStopped":26,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":26},[9],{"measure":10,"description":11,"timeFrame":12},"Objective response rate","RECIST 1.1","Month 6 and Month 12",[14,18,22],{"measure":15,"description":16,"timeFrame":17},"Radiographic response","By RECIST 1.1","Month 6 and Month 12, Month 18, Month 24, Month 30 and Month 36",{"measure":19,"description":20,"timeFrame":21},"Change in Quality of Life score","By EQ-5D-5L. Score range from 0-100.The higher the score the better quality of life","Baseline, Month 6 and Month 12",{"measure":23,"description":24,"timeFrame":25},"Health-economic impact of belzutifan","By per-patient emergence department and inpatient cost","Month 6, Month 12, Month,18, Month 24, Month 30, Month 36",null,{"allocation":26,"interventionModel":26,"interventionModelDescription":26,"primaryPurpose":26,"observationalModel":28,"timePerspective":29,"maskingInfo":26},"CASE_ONLY","PROSPECTIVE","Adult patients diagnosed with VHL syndrome who choose to use belzutifan for their treatment will be identified and invited to participate in this registry. Clinical data, laboratory tests, imaging results and QOLs will be collected from subjects at baseline, every 3 months for the first year, then every 6 months until month 36 or cessation of the medication, whichever occurs first.","Adult patients diagnosed with VHL syndrome who choose to use belzutifan for their treatment",[33],{"label":34,"type":26,"description":35,"interventionNames":26},"Belzutifan Group","Subjects received Belzutifan",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"David Ka-Wai LEUNG, FRCS, MBChB","CONTACT","35053933","davidleung@surgery.cuhk.edu.hk",[43],{"facility":44,"status":26,"city":45,"state":26,"zip":26,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":26},"Prince of Wales Hospital","Shatin","Hong Kong","HK",{"type":49,"coordinates":50},"Point",[51,52],114.18333,22.38333,{"lat":52,"lon":51},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","NG Chi Fai","Professor","100635578",false,"NCT07554508","Belzutifan VHL RCC HK Prospective Registry","A Prospective Registry for Belzutifan in the Treatment of Von Hippel-Lindau (VHL) Disease","Inclusion Criteria:\n\n* Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and\u002For genetic diagnosis.\n* The patient decided to use Belzutifan for their treatment.\n\nExclusion Criteria:\n\n* Tumour requiring immediate resection.\n* Pregnancy or unwillingness to use contraception if of childbearing potential.\n* Uncontrolled comorbidities (e.g., active infection, severe cardiopulmonary disease).","ALL","18 Years",{"count":67,"type":68},100,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.",[72],"VHL - Von Hippel-Lindau Syndrome","NOT_YET_RECRUITING","2026-04-29",{"date":76,"type":77},"2026-05-05","ACTUAL",{"date":79,"type":68},"2026-05",{"date":81,"type":68},"2029-03-31",{"name":5,"class":6},1]